FDA Cautious On Forced Rx-To-OTC Switches
This article was originally published in The Tan Sheet
While FDA has concluded internally it has the authority to determine whether a drug should be Rx or OTC, the agency is being cautious about an official announcement of its position
You may also be interested in...
FDA may rely on a drug's foreign OTC marketing experience to determine whether an Rx product should be switched OTC in the U.S. without sponsor consent, Commissioner Mark McClellan, MD/PhD, said at a Manhattan Institute roundtable discussion for buyside analysts May 16
A forced OTC switch of Zyrtec would deprive consumers of the "health information component" doctors provide, which is needed for optimal care, Pfizer CEO Henry McKinnell said during the firm's April 24 annual meeting in Ann Arbor, Mich
FDA plans to take a more active role in initiating Rx-to OTC switches in coming years, Senior Associate Commissioner for Management & Systems Jeff Weber said Feb. 3